Zoetis is trading at $83.00, up +4.11%, with no clearly confirmed catalyst directly explaining the November 2 move. - Coverage highlighted FDA approval of Convenia RTU for Dogs, announced October 20 and described as incremental for near-term results; available reporting does not link it to this session’s rise. - The supplied market picture is mixed, not a clear same-direction broad-market explanation. - Zoetis is due to report Q3 results November 5.